Title : Trimethylamine and Trimethylamine-n-oxide levels in Coronary heart disease patients with atrial fibrillation paroxysm
Plasma trimethylamine (TMA) and plasma trimethylamine-N-oxide (TMAO) play important role in dyslipidemia, obesity, chronic kidney disease and heart failure pathogenesis. We studied the role of atrial fibrillation (AF) in patients with coronary artery disease (CAD). 164 patients were examined, which included 124 CAD patients during AF paroxysm (70 patients) and without cardiac arrhythmias (54 patients). All studied had an analysis of general clinical and instrumental laboratory parameters, as well as the level of TMA and TMAO of blood plasma. A significant increase in the level of TMA and TMAO was revealed in patients with CAD without cardiac arrhythmias by 20.67% and 23.94%, respectively. In addition, a significant increase in TMA and TMAO was detected in patients with CAD with AF paroxysm compared with healthy controls by 30.29% and 98.12%. In CAD patients with AF paroxysm, there were no significant differences at the level of blood TMA. However, a highly significant increase in the level of TMAO by 59.85% was revealed. In the course of the work, a correlation analysis was performed between the level of TMA and TMAO. Correlations between the plasma TMA level and the age of patients (r = 0.584; p <0.01), BMI (r = 0.351; p <0.01), LDL (r = 0.220; p <0.05) and GFR were revealed (r = 0.239; p <0.05). Blood plasma and age of patients with TMAO (r = 0.634; p <0.01), BMI (r = 0.522; p <0.01), GFR (r = 0.327; p <0.01), as well as the level uric acid (r = 0.334; p <0.05), HDL (r = -0.411; p <0.01) and K + blood plasma (r = 0.761; p <0.01). The data obtained indicate the importance of further studying the state of the intestinal microbiome and its metabolites in CAD patients with AF paroxysms.